Pathwork Diagnostics Inc. Appoints Lee McCracken as CEO
News Nov 06, 2012
"On behalf of Pathwork's board and investors, I am delighted to welcome Mr. McCracken to the Pathwork team," said Peter Klemm, Ph.D., Chairman of the Board. "Lee, with his considerable leadership and corporate development experience, is an outstanding choice to lead Pathwork to the next level of success," said Dr. Klemm.
"I am truly pleased to join Pathwork at this exciting time in the company's history," said Mr. McCracken. "I believe the Tissue of Origin Test is positioned to become the standard of care for difficult-to-diagnose cancer tumors. Furthermore, Pathwork's proprietary informatics platform - which enabled the creation of the Tissue of Origin Test - has significant potential for developing new products. I look forward to leading the company's next stage of growth."
Lee McCracken, who serves on the company's Board of Directors, has over 20 years of experience in the life sciences, spanning novel high-value diagnostics, specialty pharmaceuticals and platform technologies in both private and public companies. He joins Pathwork following seven years as Corporate Head of Business Development at Prometheus Laboratories, a leading personalized healthcare company in gastroenterology and oncology. Prior to Prometheus, Mr. McCracken served as Senior Vice President of Pharmaceutical Business Development at Diversa Corporation. Earlier in his career, he held leadership roles with GenStar Therapeutics, CombiChem and Allergan Americas.
Before pursuing operating and corporate development roles in the life sciences, Mr. McCracken was a venture capitalist with 3i Capital and Union Venture. Mr. McCracken holds a B.S. from Santa Clara University, a Master of Computer Science from University of Dayton and an M.B.A. from UCLA Anderson School of Management.
RNA That Helps Grow Blood Vessels Could Aid Heart Disease ResearchNews
STEEL, a noncoding RNA, acts on genes to stimulate produce of blood vessels, a finding which could advance efforts to combat heart disease.READ MORE
Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast CancerNews
A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE